{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:47:58Z","timestamp":1763347678218},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2008,8,14]],"date-time":"2008-08-14T00:00:00Z","timestamp":1218672000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s00120-008-1822-2","type":"journal-article","created":{"date-parts":[[2008,8,12]],"date-time":"2008-08-12T11:26:04Z","timestamp":1218540364000},"page":"1122-1127","source":"Crossref","is-referenced-by-count":3,"title":["Aktive Immuntherapie urologischer Tumoren und tumorbedingte Immunsuppression","Active immunotherapy of urologic malignancies and tumor-mediated immunosuppression"],"prefix":"10.1007","volume":"47","author":[{"given":"H.","family":"K\u00fcbler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,14]]},"reference":[{"key":"1822_CR1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0090-4295(99)80301-X","volume":"46","author":"Blades","year":"1995","unstructured":"Blades RA, Keating PJ, McWilliam LJ et al. (1995) Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 46: 681\u20136867","journal-title":"Urology"},{"key":"1822_CR2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/jgm.1051","volume":"9","author":"Brill","year":"2007","unstructured":"Brill TH, Kubler HR, Randenborgh H von et al. (2007) Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer \u2013 a phase I clinical trial. J Gene Med 9: 547\u2013560","journal-title":"J Gene Med"},{"key":"1822_CR3","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.4049\/jimmunol.162.10.5728","volume":"162","author":"Bronte","year":"1999","unstructured":"Bronte V, Chappell DB, Apolloni E et al. (1999) Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 162: 5728\u20135737","journal-title":"J Immunol"},{"key":"1822_CR4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S1471-4906(03)00132-7","volume":"24","author":"Bronte","year":"2003","unstructured":"Bronte V, Serafini P, Mazzoni A et al. (2003) L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 24: 302\u2013306","journal-title":"Trends Immunol"},{"key":"1822_CR5","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1002\/eji.200526128","volume":"35","author":"Coles","year":"2005","unstructured":"Coles AJ, Thompson S, Cox AL et al. (2005) Dehydroepiandrosterone replacement in patients with Addison\u2019s disease has a bimodal effect on regulatory (CD4+CD25hi and CD4+FoxP3+) T cells. Eur J Immunol 35: 3694\u20133703","journal-title":"Eur J Immunol"},{"key":"1822_CR6","doi-asserted-by":"crossref","unstructured":"Dannull J, Su Z, Kubler HR et al. (2006) Enhancement of vaccine-mediated antitumor immunity in renal cell carcinoma (RCC) patients after in vivo depletion of regulatory T cells. Results from a phase-I clinical trail. AUA Annual Meeting","DOI":"10.1016\/S0022-5347(18)32654-5"},{"key":"1822_CR7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ccr.2005.01.027","volume":"7","author":"Drake","year":"2005","unstructured":"Drake CG, Doody AD, Mihalyo MA et al. (2005) Androgen ablation mitigates tolerance to a prostate\/prostate cancer-restricted antigen. Cancer Cell 7: 239\u2013249","journal-title":"Cancer Cell"},{"key":"1822_CR8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04483","volume":"438","author":"Ferrara","year":"2005","unstructured":"Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438: 967\u2013974","journal-title":"Nature"},{"key":"1822_CR9","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1158\/1078-0432.CCR-04-1883","volume":"11","author":"Frankenberger","year":"2005","unstructured":"Frankenberger B, Pohla H, Noessner E et al. (2005) Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs. Clin Cancer Res 11: 1733\u20131742","journal-title":"Clin Cancer Res"},{"key":"1822_CR10","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"Gabrilovich","year":"1996","unstructured":"Gabrilovich DI, Chen HL, Girgis KR et al. (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2: 1096\u20131103","journal-title":"Nat Med"},{"key":"1822_CR11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMp030061","volume":"349","author":"George","year":"2003","unstructured":"George DJ, Kaelin WG Jr (2003) The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 349: 419\u2013421","journal-title":"N Engl J Med"},{"key":"1822_CR12","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1084\/jem.20051511","volume":"202","author":"Ghiringhelli","year":"2005","unstructured":"Ghiringhelli F, Menard C, Terme M et al. (2005) CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202: 1075-1085","journal-title":"J Exp Med"},{"key":"1822_CR13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1074-7613(00)80101-6","volume":"11","author":"Gilboa","year":"1999","unstructured":"Gilboa E (1999) The makings of a tumor rejection antigen. Immunity 11: 263\u2013270","journal-title":"Immunity"},{"key":"1822_CR14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.0105-2896.2004.00139.x","volume":"199","author":"Gilboa","year":"2004","unstructured":"Gilboa E, Vieweg J (2004) Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199: 251\u2013263","journal-title":"Immunol Rev"},{"key":"1822_CR15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cell.2005.10.036","volume":"124","author":"Grunewald","year":"2006","unstructured":"Grunewald M, Avraham I, Dor Y et al. (2006) VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124: 175\u2013189","journal-title":"Cell"},{"key":"1822_CR16","first-page":"2444","volume":"60","author":"Hurwitz","year":"2000","unstructured":"Hurwitz AA, Foster BA, Kwon ED et al. (2000) Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60: 2444\u20132448","journal-title":"Cancer Res"},{"key":"1822_CR17","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nature04186","volume":"438","author":"Kaplan","year":"2005","unstructured":"Kaplan RN, Riba RD, Zacharoulis S et al. (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820\u2013827","journal-title":"Nature"},{"key":"1822_CR18","first-page":"2526","volume":"63","author":"Krishnan","year":"2003","unstructured":"Krishnan L, Sad S, Patel GB, Sprott GD (2003) Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge. Cancer Res 63: 2526\u20132534","journal-title":"Cancer Res"},{"key":"1822_CR19","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1053\/j.seminoncol.2006.06.011","volume":"33","author":"Kubler","year":"2006","unstructured":"Kubler H, Vieweg J (2006) Vaccines in renal cell carcinoma. Semin Oncol 33: 614\u2013624","journal-title":"Semin Oncol"},{"key":"1822_CR20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4049\/jimmunol.181.1.346","volume":"181","author":"Kusmartsev","year":"2008","unstructured":"Kusmartsev S, Eruslanov E, Kubler H et al. (2008) Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol 181(1): 346\u2013353","journal-title":"J Immunol"},{"key":"1822_CR21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10555-006-9002-6","volume":"25","author":"Kusmartsev","year":"2006","unstructured":"Kusmartsev S, Gabrilovich DI (2006) Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 25: 323\u2013331","journal-title":"Cancer Metastasis Rev"},{"key":"1822_CR22","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.4049\/jimmunol.175.7.4583","volume":"175","author":"Kusmartsev","year":"2005","unstructured":"Kusmartsev S, Nagaraj S, Gabrilovich DI (2005) Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 175: 4583\u20134592","journal-title":"J Immunol"},{"key":"1822_CR23","doi-asserted-by":"crossref","unstructured":"Kusmartsev S, Su Z, Heiser A et al. (2008) Reversal of myeloid-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res (in press)","DOI":"10.1158\/1078-0432.CCR-08-0165"},{"key":"1822_CR24","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.4049\/jimmunol.175.11.7746","volume":"175","author":"Maker","year":"2005","unstructured":"Maker AV, Attia P, Rosenberg SA (2005) Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175: 7746\u20137754","journal-title":"J Immunol"},{"key":"1822_CR25","first-page":"84","volume":"9","author":"Propper","year":"2003","unstructured":"Propper DJ, Chao D, Braybrooke JP et al. (2003) Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. Clin Cancer Res 9: 84\u201392","journal-title":"Clin Cancer Res"},{"key":"1822_CR26","doi-asserted-by":"crossref","first-page":"5622","DOI":"10.1158\/1078-0432.CCR-06-1204","volume":"12","author":"Ruan","year":"2006","unstructured":"Ruan J, Hyjek E, Kermani P et al. (2006) Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin\u2019s lymphoma. Clin Cancer Res 12: 5622\u20135631","journal-title":"Clin Cancer Res"},{"key":"1822_CR27","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI200320274","volume":"112","author":"Sakaguchi","year":"2003","unstructured":"Sakaguchi S (2003) The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery. J Clin Invest 112: 1310\u20131312","journal-title":"J Clin Invest"},{"key":"1822_CR28","first-page":"4756","volume":"61","author":"Schmielau","year":"2001","unstructured":"Schmielau J, Finn OJ (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 61: 4756\u20134760","journal-title":"Cancer Res"},{"key":"1822_CR29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1084\/jem.193.11.F41","volume":"193","author":"Shevach","year":"2001","unstructured":"Shevach EM (2001) Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 193: 41\u201346","journal-title":"J Exp Med"},{"key":"1822_CR30","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1158\/0008-5472.CAN-06-4174","volume":"67","author":"Sinha","year":"2007","unstructured":"Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S (2007) Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67: 4507\u20134513","journal-title":"Cancer Res"},{"key":"1822_CR31","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/eji.200425143","volume":"34","author":"Tang","year":"2004","unstructured":"Tang Q, Boden EK, Henriksen KJ et al. (2004) Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol 34: 2996\u20133005","journal-title":"Eur J Immunol"},{"key":"1822_CR32","first-page":"29","volume":"9","author":"Vieweg","year":"2007","unstructured":"Vieweg J (2007) Immunotherapy for advanced prostate cancer. Rev Urol 9(Suppl 1): 29\u201338","journal-title":"Rev Urol"},{"key":"1822_CR33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/ncpuro0079","volume":"2","author":"Vieweg","year":"2005","unstructured":"Vieweg J, Dannull J (2005) Technology insight: vaccine therapy for prostate cancer. Nat Clin Pract Urol 2: 44\u201351","journal-title":"Nat Clin Pract Urol"},{"key":"1822_CR34","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/1078-0432.CCR-06-1924","volume":"13","author":"Vieweg","year":"2007","unstructured":"Vieweg J, Su Z, Dahm P, Kusmartsev S (2007) Reversal of tumor-mediated immunosuppression. Clin Cancer Res 13: 727\u2013732","journal-title":"Clin Cancer Res"},{"key":"1822_CR35","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2006-01-0177","volume":"108","author":"Wei","year":"2006","unstructured":"Wei S, Kryczek I, Zou W (2006) Regulatory T-cell compartmentalization and trafficking. Blood 108: 426\u2013431","journal-title":"Blood"},{"key":"1822_CR36","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nature04790","volume":"441","author":"Williams","year":"2006","unstructured":"Williams MA, Tyznik AJ, Bevan MJ (2006) Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 441: 890\u2013893","journal-title":"Nature"},{"key":"1822_CR37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1365-2567.2002.01412.x","volume":"106","author":"Wing","year":"2002","unstructured":"Wing K, Ekmark A, Karlsson H et al. (2002) Characterization of human CD25+CD4+ T cells in thymus, cord and adult blood. Immunology 106: 190\u2013199","journal-title":"Immunology"},{"key":"1822_CR38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1006\/jtbi.2000.2147","volume":"206","author":"Yates","year":"2000","unstructured":"Yates A, Bergmann C, Van Hemmen JL et al. (2000) Cytokine-modulated regulation of helper T cell populations. J Theor Biol 206: 539\u2013560","journal-title":"J Theor Biol"},{"key":"1822_CR39","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.4049\/jimmunol.156.5.1916","volume":"156","author":"Young","year":"1996","unstructured":"Young MR, Wright MA, Matthews JP et al. (1996) Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. J Immunol 156: 1916\u20131922","journal-title":"J Immunol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-008-1822-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-008-1822-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-008-1822-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T14:39:39Z","timestamp":1684507179000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-008-1822-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,14]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["1822"],"URL":"https:\/\/doi.org\/10.1007\/s00120-008-1822-2","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,14]]}}}